Sulglicotide

Summary

Sulglicotide is an oral, prescription‑only polysulfated glycopeptide used as a gastric mucosal protectant. It is employed to alleviate symptoms and improve endoscopic findings in various dyspeptic conditions, including chronic superficial gastritis, non‑ulcer dyspepsia, duodenogastric reflux, and to lessen mucosal injury caused by non‑steroidal anti‑inflammatory drugs (NSAIDs).

Mechanism of Action

Sulglicotide acts as a cytoprotective agent by stabilising lysosomal membranes in gastric epithelial cells, thereby preventing the release of lytic enzymes that contribute to mucosal damage. This lysosomal protection, together with an increase in the gastric mucosa’s defensive capacity, reduces inflammation and promotes healing of the gastric and duodenal lining.

What the Research Shows

Clinical evidence for sulglicotide consists of several small Italian studies. A randomized single‑blind trial (n=50) showed symptom and histologic improvement comparable to esaprazole in chronic superficial antral gastritis, without H. pylori eradication. A double‑blind placebo‑controlled study (n=30) in patients taking diclofenac demonstrated that sulglicotide limited NSAID‑induced injury to mild hyperemia versus ulceration in the placebo group. Open‑label investigations in non‑ulcer dyspepsia, duodenogastric reflux, and chronic gastritis reported marked symptom relief and endoscopic improvement after 8 weeks of 200 mg three times daily. In vitro and ex‑vivo rat experiments confirmed dose‑dependent lysosomal membrane stabilization, supporting its cytoprotective profile.

Reported Benefits

Evidence suggests sulglicotide can reduce dyspeptic symptoms, improve endoscopic appearance of the gastric mucosa, and protect against NSAID‑induced gastric injury. Studies consistently reported statistically significant symptom relief and mucosal healing, and no adverse events were noted in the trials, indicating a favorable tolerability profile within the short‑term treatment periods evaluated.

Limitations of the Evidence

The available data are limited to small, mostly open or single‑blind studies, many conducted in Italy, with short treatment durations (6–8 weeks). Large, double‑blind, multicenter trials are lacking, and comparative effectiveness versus standard acid‑suppression therapy remains unclear. No data address long‑term safety, H. pylori eradication, or use in broader populations.

Safety Considerations

Across the reported trials, sulglicotide was well tolerated, and no side effects were recorded. However, safety information is derived from limited sample sizes and short‑term use; therefore, rare or delayed adverse effects have not been characterised. Caution is advised in patients with unknown allergies to glycopeptide compounds.

How It Is Administered

Sulglicotide is administered orally, typically as 200 mg tablets taken three times daily (t.i.d.). The dosing regimen used in clinical studies spanned 6 to 8 weeks. Formulations are marketed as standard oral tablets.

Routes of Administration

Goals & Uses

• Mucosal cytoprotectionGastrointestinalModerate
• Pepsin inhibitionEnzyme InhibitionLow
• Gastritis managementGastrointestinalModerate
• Peptic ulcer treatmentGastrointestinalModerate

Contraindications

• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Hypersensitivity to porcine-derived productsAllergy / ImmunologicalHigh

Adverse Effects

• Allergic reactionImmunologicRareImmune-mediated hypersensitivity response
• Abdominal discomfortGastrointestinalUncommon
• NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
• DiarrheaGastrointestinalUncommonLoose or frequent stools

Drug Interactions

• AntacidsLow
• NSAIDsModerateMay increase renal risk in susceptible patients

Population Constraints

• Pediatric patientsAgeRelative
• Patients with porcine product allergyAllergyAbsolute
• Pregnant womenReproductiveRelative

Regulatory Status

• European UnionApprovedApproved: Peptic ulcer disease, GastritisApproved in Italy and select European markets; not universally approved across all EU member states.
• United StatesUnapprovedNot approved by the FDA; not commercially available in the United States.
• United KingdomUnknownNot widely referenced in MHRA approved product lists; availability uncertain.

Approved in Italy and some other European and Asian markets for gastric and duodenal ulcer treatment. Not approved by the US FDA. Regulatory status varies widely by country.

Evidence & Sources

• [Esaprazole vs sulglicotide in the treatment of dyspeptic patients with chronic superficial gastritis of the antrum]
  Journal ArticleModerateSabbatini F, et al.1991-01-01T00:00:00.000000Z
• [Sulglicotide in the prevention of gastric disease induced by NSAID. Double-blind controlled study versus placebo]
  Journal ArticleModerateMagarò M, et al.1989-01-01T00:00:00.000000Z
• [Therapy of non-ulcer dyspepsia]
  Journal ArticleModerateCortese I, Maselli MA1990-01-01T00:00:00.000000Z
• [Sulglicotide in the treatment of dyspeptic patients with duodenogastric reflux]
  Journal ArticleLowBertoldi M, et al.1990-01-01T00:00:00.000000Z
• Gastroprotection and lysosomal membrane stabilization by sulglicotide
  Journal ArticleLowPorta R, et al.1986-01-01T00:00:00.000000Z
• [Sulglicotide in non-ulcerous dyspepsia]
  Journal ArticleLowBassi O, et al.1989-01-01T00:00:00.000000Z

Frequently Asked Questions